Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

J.P. Morgan Lowers Biovail to 'Neutral'

J.P. Morgan downgraded Biovail (BVF) to neutral from overweight.

Analyst Corey Davis says he has little doubt the stock will sell-off Friday morning, and thinks it will remain "dead money" until the Securities & Exchange Commission's accounting inquiry ends. Davis says even if nothing is found, the investigation will probably take months to resolve.

Davis says strength in Wellbutrin XL is apparent in drug trends, and is unlikely to surprise on the upside, but provides some comfort on the earnings floor. He thinks this may be a bottom, but he thought this before, and says it's difficult to see outperformance over the next several months with yet another cloud.

blog comments powered by Disqus